DEF 14A: Septerna, Inc. Announces 2025 Annual Meeting of Stockholders

Septerna, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Septerna, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, at 2:00 p.m. Pacific Time.
• Stockholders of record as of April 21, 2025, are entitled to vote on the election of two Class I directors, each to serve until the 2028 Annual Meeting, and to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors recommends voting FOR the election of Abraham Bassan, M.S. and Alan Ezekowitz, M.D., D.Phil. as Class I directors and FOR the ratification of Ernst & Young LLP's appointment.
• The company is providing access to proxy materials online, mailing a Notice of Internet Availability of Proxy Materials on or about April 29, 2025.
• Stockholders can vote online, by telephone, or by mail, with specific deadlines for each method.
• The company had 44,515,703 shares of common stock outstanding as of April 21, 2025.
• The board of directors consists of seven members divided into three classes with staggered three-year terms.
• The company incurred $2,444,172 in audit fees from Ernst & Young LLP for the fiscal year 2024.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming annual meeting and proposals. It expresses confidence in the director nominees and the accounting firm, but does not contain overly positive or negative language.

Positives

• The company is leveraging technology to enhance stockholder access to the Annual Meeting through a virtual format.
• The board of directors is recommending qualified candidates for election as directors.
• The audit committee is recommending the ratification of a reputable independent registered public accounting firm.
• The company is providing multiple methods for stockholders to vote, including online, telephone, and mail.

Future Outlook

The company plans to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

Management Comments

• The board of directors recommends a vote FOR the election of each of the two nominees for Class I directors and FOR the ratification of the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2025, as disclosed in more detail in the accompanying proxy statement.
• We believe that the virtual-only meeting format will give stockholders the opportunity to participate fully and equally, and without cost, and to exercise the same rights as if they had attended an in-person meeting.

Industry Context

This is a standard proxy statement for a publicly traded company, covering routine matters such as director elections and auditor ratification. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation and corporate governance practices appear generally consistent with industry standards for similarly sized biopharmaceutical companies.
• The audit fee structure and pre-approval policies are in line with regulatory requirements and best practices.
• Comparable companies such as Ultragenyx Pharmaceuticals Inc. (Nasdaq: RARE), Agenus, Inc. (Nasdaq: AGEN), Beigene, Ltd. (Nasdaq: BGNE), Neurocrine Biosciences, Inc. (Nasdaq: NBIX), and Organon & Co (Nasdaq: OGN) have similar board structures and compensation policies.
• The virtual annual meeting format is increasingly common among public companies to improve shareholder access and reduce costs, aligning with practices seen at companies like Fulcrum Therapeutics, Inc. (Nasdaq: FULC) and Pliant Therapeutics, Inc. (Nasdaq: PLRX).

Management Changes

Related Party Transactions

• In 2023 and 2024, Septerna issued Series B convertible preferred stock to related parties, including Third Rock Ventures, RA Capital, and Samsara BioCapital.
• Third Rock Ventures provided consulting services to Septerna, with costs totaling $0.3 million in both 2023 and 2024.
• Dr. Ezekowitz served as interim Chief Medical Officer through Third Rock Ventures and received stock options as compensation.

Stakeholder Impact

• Shareholders are encouraged to participate in the voting process to influence the company's direction.
• Employees are indirectly affected by the election of directors and the ratification of the accounting firm.
• The company's financial stability and governance practices impact its relationships with suppliers and creditors.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 17, 2025.
• The company will announce the voting results and file a Form 8-K with the SEC.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Stockholders, Ernst & Young, Accounting Firm, Corporate Governance, Voting, Septerna